Skip to main content

Compugen Reports $2.6M in Revenues for Q1

NEW YORK, April 30 - Compugen today reported revenues of $2.6 million and a net loss of $2.3 million for the first quarter ending March 31.

 

Revenues, which included $455,000 from R&D grants, were down from the $2.8 million for the year-ago quarter, The Tel Aviv, Israel-based firm said. Net loss, including a non-cash charge of $94,000 for amortization of deferred compensation, dropped from the year-ago quarter's loss of $3.2 million. The company reported R&D expenses of   $3.2 million for the quarter, compared to $3.4 million for the same quarter in 2002.

 

The company reported $67.3 million in cash, cash equivalents and securities on hand as of March 32, comparable to the year-ago quarter and including a $1.7 million private placement by its ag-bio subsidiary Evogen.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.